These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 16898852)

  • 1. Minimizing bone abnormalities in children with renal failure.
    Ziólkowska H
    Paediatr Drugs; 2006; 8(4):205-22. PubMed ID: 16898852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to minimize bone disease in renal failure.
    Martin KJ; González EA
    Am J Kidney Dis; 2001 Dec; 38(6):1430-6. PubMed ID: 11728986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment.
    Sanchez CP
    Paediatr Drugs; 2003; 5(11):763-76. PubMed ID: 14580225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
    Hottelart C; Bako G; Oprisiu R; Georgita A; Presne C; Sarraj A; Morinière P; el Esper N; Fournier A
    Nephrologie; 2000; 21(6):275-82. PubMed ID: 11117106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia.
    Locatelli F; Cannata-Andía JB; Drüeke TB; Hörl WH; Fouque D; Heimburger O; Ritz E
    Nephrol Dial Transplant; 2002 May; 17(5):723-31. PubMed ID: 11981055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for bone disease in children with chronic kidney disease.
    Geary DF; Hodson EM; Craig JC
    Cochrane Database Syst Rev; 2010 Jan; (1):CD008327. PubMed ID: 20091666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of renal osteodystrophy in children.
    Tasic V
    Turk J Pediatr; 2005; 47 Suppl():13-8. PubMed ID: 15884662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.
    Fournier A; Morinière PH; Oprisiu R; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
    Nephron; 1995; 71(3):254-83. PubMed ID: 8569975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in pediatric metabolic bone disease: the consequences of altered phosphate homeostasis in renal insufficiency and hypophosphatemic vitamin D-resistant rickets.
    Pettifor JM
    Bone Miner; 1990 Jun; 9(3):199-214. PubMed ID: 2163713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy.
    Hernandez JD; Wesseling K; Salusky IB
    Semin Dial; 2005; 18(4):290-5. PubMed ID: 16076350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of renal osteodystrophy in peritoneal dialysis.
    Weinreich T
    Kidney Int; 1998 Dec; 54(6):2226-33. PubMed ID: 9853289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
    Coburn JW; Elangovan L
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
    Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
    J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Musculoskeletal manifestations of chronic renal failure.
    Bardin T
    Curr Opin Rheumatol; 2003 Jan; 15(1):48-54. PubMed ID: 12496510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone health and vascular calcification relationships in chronic kidney disease.
    Spasovski GB
    Int Urol Nephrol; 2007; 39(4):1209-16. PubMed ID: 17899431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of renal osteodystrophy in children on continuous ambulatory peritoneal dialysis.
    Yalçinkaya F; Ince E; Tümer N; Ensari A; Ozkaya N
    Pediatr Int; 2000 Feb; 42(1):53-7. PubMed ID: 10703235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
    Lorenzo Sellares V; Torres Ramírez A
    Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.